Simon R. Dixon

Simon R. Dixon

Auto-generated profile, based on publicly available information

Simon R. Dixon

Corewell Health William Beaumont University Hospital, Royal Oak, MI (S.R.D.).

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2015 in Coronary Artery Disease
Verified
Journal Article
Closed access
IHIvan D. Hanson
Ivan D. Hanson
JGJames A. Goldstein
James A. Goldstein
SDSimon R. Dixon
Simon R. Dixon
GSGregg W. Stone
Gregg W. Stone
Intravascular ultrasound (IVUS) studies analyzing target lesion plaque burden (PB) have established that invasive coronary angiography commonly underestimates lesion length, predisposing to 'geographic miss' during a percutaneous coronary intervention, which has been associated with adverse outcomes. Plaque composition may also influence stent outcome. The present study used near-infrared spectroscopy and IVUS (NIRS-IVUS) to assess the prevalence of PB and lipid-core plaque (LCP) extending beyond angiographic borders of target lesions. Fifty-eight patients (58 lesions) undergoing NIRS-IVUS were identified. By invasive coronary angiography, target lesion length and minimum lumen diameter were measured. Plaque, defined as NIRS-IVUS atheroma (either PB>40% or LCP), was identified adjacent to the angiographic-defined lesion margins. By NIRS-IVUS, atheroma (either PB>40% or LCP) was identified beyond angiographic lesion margins in 52/58 (90%) lesions. The mean lesion length was 13.4±5.9 mm by angiography and 19.8±7.0 mm (P<0.0001) by NIRS-IVUS. LCP extending beyond the angiographic border was observed in 30/58 (52%) lesions. NIRS-IVUS imaging shows that target lesion length is commonly underestimated by angiography alone. This finding may have implications for stent length selection and avoidance of geographic miss.

1 December 2022 in Catheterization and Cardiovascular Interventions
Verified
Journal Article
Closed access
MRMaher Rabah
Maher Rabah
SASorcha Allen
Sorcha Allen
AAAmr E. Abbas
Amr E. Abbas
SDSimon Dixon
Simon Dixon

1 February 2024 in Circulation: Cardiovascular Interventions
Verified
Journal Article
Closed access
RMRyan D. Madder
Ryan D. Madder
MSMilan Seth
Milan Seth
KFKathleen Frazier
Kathleen Frazier
SDSimon Dixon
Simon Dixon
MKMilind Karve
Milind Karve
HGHitinder S. Gurm
Hitinder S. Gurm
BACKGROUND: Improved radiation safety practices are needed across hospitals performing percutaneous coronary intervention (PCI). This study was performed to assess the temporal trend in PCI radiation doses concurrent with the conduct of a statewide radiation safety initiative. METHODS: A statewide initiative to reduce PCI radiation doses was conducted in Michigan between 2017 and 2021 and included focused radiation safety education, reporting of institutional radiation doses, and implementation of radiation performance metrics for hospitals. Using data from a large statewide registry, PCI discharges between July 1, 2016, and July 1, 2022, having a procedural air kerma (AK) recorded were analyzed for temporal trends. A multivariable regression analysis was performed to determine whether declines in procedural AK over time were attributable to changes in known predictors of radiation doses. RESULTS: Among 131 619 PCI procedures performed during the study period, a reduction in procedural AK was observed over time, from a median dose of 1.46 (0.86–2.37) Gy in the first year of the study to 0.97 (0.56–1.64) Gy in the last year of the study ( P <0.001). The proportion of cases with an AK ≥5 Gy declined from 4.24% to 0.86% over the same time period ( P <0.0001). After adjusting for variables known to impact radiation doses, a 1-year increase in the date of PCI was associated with a 7.61% (95% CI, 7.38%–7.84%) reduction in procedural AK ( P <0.0001). CONCLUSIONS: Concurrent with the conduct of a statewide initiative to reduce procedural radiation doses, a progressive and significant decline in procedural radiation doses was observed among patients undergoing PCI in the state of Michigan.

6 February 2024 in Journal of the American Heart Association
Verified
Journal Article
Open access
IHIvan D. Hanson
Ivan D. Hanson
ARAkash Rusia
Akash Rusia
APAndres Palomo
Andres Palomo
ATAdam Tawney
Adam Tawney
TPTimothy Pow
Timothy Pow
WOWilliam O'NEill
William O'NEill
Background: The Society for Cardiovascular Angiography and Interventions proposed a staging system (A–E) to predict prognosis in cardiogenic shock. Herein, we report clinical outcomes of the RECOVER III study for the first time, according to Society for Cardiovascular Angiography and Interventions shock classification. Methods and Results: The RECOVER III study is an observational, prospective, multicenter, single‐arm, postapproval study of patients with acute myocardial infarction with cardiogenic shock undergoing percutaneous coronary intervention with Impella support. Patients enrolled in the RECOVER III study were assigned a baseline Society for Cardiovascular Angiography and Interventions shock stage. Staging was then repeated within 24 hours after initiation of Impella. Kaplan‐Meier survival curve analyses were conducted to assess survival across Society for Cardiovascular Angiography and Interventions shock stages at both time points. At baseline assessment, 16.5%, 11.4%, and 72.2% were classified as stage C, D, and E, respectively. At ≤24‐hour assessment, 26.4%, 33.2%, and 40.0% were classified as stage C, D, and E, respectively. Thirty‐day survival among patients with stage C, D, and E shock at baseline was 59.7%, 56.5%, and 42.9%, respectively ( P =0.003). Survival among patients with stage C, D, and E shock at ≤24 hours was 65.7%, 52.1%, and 29.5%, respectively ( P <0.001). After multivariable analysis of impact of shock stage classifications at baseline and ≤24 hours, only stage E classification at ≤24 hours was a significant predictor of mortality (odds ratio, 4.8; P <0.001). Conclusions: In a real‐world cohort of patients with acute myocardial infarction with cardiogenic shock undergoing percutaneous coronary intervention with Impella support, only stage E classification at ≤24 hours was significantly predictive of mortality, suggesting that response to therapy may be more important than clinical severity of shock at presentation.

7 January 2025 in Journal of the Society for Cardiovascular Angiography & Interventions
Verified
Journal Article
Open access
IHIvan D. Hanson
Ivan D. Hanson
APAndres Palomo
Andres Palomo
ATAdam Tawney
Adam Tawney
SDSimon R. Dixon
Simon R. Dixon
DBDana Bentley
Dana Bentley
WOWilliam W. O’nEill
William W. O’nEill
The present analysis reports characteristics and outcomes of Society of Cardiovascular Angiography & Interventions (SCAI) stage E shock patients with acute myocardial infarction with cardiogenic shock (AMICS) undergoing percutaneous coronary intervention (PCI) who improved to stage C or D within 24 hours of Impella support ("responders") vs those patients who remained in stage E ("nonresponders"). The SCAI shock stage was assigned prior to initiation of Impella, and a second SCAI shock classification was performed within 24 hours of Impella support. SCAI shock stage was assigned independently by 2 reviewers; in cases where there was a discrepancy, a third reviewer adjudicated the stage assignment. Criteria such as a low pH (≤7.1), the need for multiple vasopressors/mechanical circulatory support devices, or the need for cardiopulmonary resuscitation were used to define stage E shock. Of the 415 RECOVER III patients, 298 presented in stage E shock; 152 (51.1%) were responders and 145 (48.8%) were nonresponders. Kaplan-Meier 30-day survival estimates were 56.9% and 28.6% in responders and nonresponders, respectively (P < .001). In multivariate analysis, fewer inotropic medications during Impella support (P < .0001), more lesions treated (P = .01), Impella support initiated pre-PCI (P = .03), and baseline white blood cell (P = .048) were all significant predictors for responsiveness to therapy. Stage E patients who improved to stage C/D within 24 hours of Impella support had significantly better survival than those who remained in stage E. Predictors of responsiveness to therapy were mostly related to shock treatment strategy, and not baseline characteristics. This suggests that whether stage E patients will improve with Impella support is difficult to determine at the time support is initiated, and the SCAI shock stage should be repeated within 24 hours to more accurately determine the prognosis.

1 January 2000 in Catheterization and Cardiovascular Interventions
Verified
Journal Article
Closed access
PDF file
MWMark W.I. Webster
Mark W.I. Webster
SDSimon R. Dixon
Simon R. Dixon
JOJohn A. Ormiston
John A. Ormiston
PRPeter N. Ruygrok
Peter N. Ruygrok
JSJames T. Stewart
James T. Stewart